Medication Management System MarketThe global medication management system market is on an upward trajectory, projected to surge from a value of US$ 2.7 billion in 2023 to a staggering US$ 9.0 billion by 2033, showcasing a compelling compound annual growth rate (CAGR) of 12.4%. This exponential growth is spurred by.
Social Factors, Not Biology, Boost Drug Risks in Women miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
American Regent, Inc., a Daiichi Sankyo Group company, today announced results from the phase 3 HEART-FID trial of INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart
Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, have announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity. The company reported that with this approval, INJECTAFER is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.
Background: Within the quality use of medicines (QUM) which entails timely access to, and the rational use of, medicines medicine safety is a global health priority. In multicultural countries, such as Australia, national medicines policies are focused on achieving QUM, although this is more challenging among their Culturally and Linguistically Diverse (CALD) patients (i.e., those from ethnic minority groups). Aim: This review aimed to identify and explore the specific challenges to achieving QUM, as experienced by CALD patients living in Australia. Method: A systematic literature search was conducted using Web of Science, Scopus, Academic search complete, CINHAL, PubMed and Medline. Qualitative studies describing any aspects of QUM among CALD patients in Australia were included. Results: Major challenges in facilitating QUM among CALD patients in Australia were identified, particularly in relation to the following medicines management pathway steps: difficulties around participation in treatment decision-making alongside deficiencies in information provision about medicines. Furthermore, medication non-adherence was commonly observed and reported. When mapped against the bio-psycho-socio-systems model, the main contributors to the medicine management challenges identified related to “social” and “system” factors, reflecting the current health-system’s lack of capacity and resourcing to respond to patients’ low health literacy levels, communication and language barriers, and cultural and religious perceptions about medicines. Conclusion: QUM challenges were different among different ethnic groups. This review suggests a need to engage with CALD patients in co-designing culturally appropriate resources and/or interventions to enable the health-system to address the identified barriers to QUM.